Focus on SVR hinders Merck's Victrelis' German benefit review; may impact Janssen
This article was originally published in Scrip
Executive Summary
Merck & Co's hepatitis C drug, Victrelis (boceprevir), appears to offer some additional benefit for patients who have not yet developed liver cirrhosis, but the extent of the benefit is uncertain, says IQWiG, Germany's Institute for Quality and Efficiency in Healthcare (IQWiG). Meanwhile, Janssen-Cilag, which markets competitor drug Incivo (telaprevir) is likely to be taking note, particularly given the institute's approach to sustained virological response (SVR) as an outcome. Work on an assessment of Incivo has already begun.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.